Cash Position - As of December 31, 2024, the company's cash and cash equivalents amounted to €81.8 million, an increase from €77.8 million as of December 31, 2023, but a decrease from €96.0 million as of September 30, 2024 [1][8] Revenue Performance - Revenues for 2024 reached €67.0 million, significantly up from €28.6 million in 2023 [4][8] - The revenue breakdown for 2024 includes €48.7 million from a milestone payment invoiced to Ipsen, €2.7 million from royalty revenue from U.S. sales of Iqirvo/elafibranor, €15.3 million from the partial recognition of deferred income, and €0.1 million from services rendered under Transition Services Agreements [5][8] Strategic Partnerships and Financing - The company received a €48.7 million milestone in August 2024 as part of its long-term strategic partnership with Ipsen, which was established in December 2021 [2] - A royalty financing deal was signed, providing up to €185 million in non-dilutive capital to fund operating expenses and capital expenditures beyond the end of 2027, contingent on future milestone revenues and approvals [3] Upcoming Financial Communications - The company plans to release its full-year 2024 financial results on April 24, 2025, along with the 2024 Universal Registration Document and the Annual Report on Form 20-F by the end of April 2025 [9]
GENFIT Announces Revenues and Cash Position as of December 31, 2024